nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-130C4F41·Framework v5.9·Pipeline v0.4·Evaluated 08 Oct 2026·OECD: 3.2 Clinical medicine·Subfield: Genetics·Basis: Full text·Type: Computational or machine-learning study

GWAS of extended prescription analgesic use identifies genetic loci in chronic pain.

Harlow et al.Harlow, Uzochukwu, Fernando et al.·2026·Nature communications·10.1038/s41467-026-71434-8 ↗

Primary claim

Integrating these genetic associations with functional data identifies potential mechanisms involved in chronic pain, implicating oligodendrocyte differentiation, neuronal guidance, endolysosomal function and post-synaptic endosome recycling.

Tentative · functional enrichments are indirect and inherit uncertainty from the prescription-based phenotype
In brief

A large two-biobank genetics resource expands analgesic-use association mapping, but the unvalidated prescription proxy limits claims about chronic-pain biology.

ReliabilityCaveats4 of 4 checks completeRead the 2 entries ↓
Abstract

Pain-related conditions are the leading cause of disability worldwide. Existing GWAS for chronic pain have mainly focused on individual pain-related disorders, which may not optimally capture the phenotype. Here, we define chronic pain based on prescription analgesic use ( ≥ 90 days) in two large biobanks (UK Biobank and FinnGen). GWAS meta-analyses of 11 prescription-based pain phenotypes identify 140 associations with chronic pain, including 78 novel (e.g. ARPP21, CNTNAP2) and 62 previously reported (e.g. SLC39A8, DCC, TRPM8) associations. Integrating these genetic associations with functional data including transcriptome-wide association studies, cell-type and pathway enrichment, and gene enrichment in mouse phenotypes identifies potential mechanisms involved in chronic pain, implicating oligodendrocyte differentiation, neuronal guidance, endolysosomal function and post-synaptic endosome recycling. Our study showcases how the use of prescription data to identify and characterize pain can provide insights into pain genetics and its underlying biology.

Key Claims

Primary finding · Tentative

Integrating these genetic associations with functional data identifies potential mechanisms involved in chronic pain, implicating oligodendrocyte differentiation, neuronal guidance, endolysosomal function and post-synaptic endosome recycling.

functional enrichments are indirect and inherit uncertainty from the prescription-based phenotype

Abstract
Secondary · Tentative

We detected many associations at loci previously reported in the literature, demonstrating that our prescription-based definitions of chronic pain are capturing relevant disease information.

known-locus overlap cannot separate pain signal from medication-use and opioid-related determinants

Results, Discovery of 140 Genetic Associations
Quote verified
Secondary · Supported

The strongest genetic correlations were found between pain duration phenotypes and depression or post-traumatic stress disorder.

reported LDSC estimates pass the stated multiple-testing threshold, subject to proxy-phenotype interpretation

Results, Shared Genetic Architecture of Pain with Neuropsychiatric and Immunological Traits
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Large two-biobank association resource

The study meta-analyses 11 prescription-derived phenotypes across UK Biobank and FinnGen, with overall sample sizes reaching 692,039 participants.

↳ Results, Discovery of 140 Genetic Associations; Table 1

#methodological rigour

Broad complementary analytical programme

Common-variant GWAS is supplemented by rare-variant burden tests, colocalisation, TWAS, cell-type analysis, mouse-phenotype enrichment, and genetic-correlation analyses.

↳ Methods, Overview of Analyses; Figure 6

#positioning

Substantive discussion of study boundaries

The Discussion identifies restrictions arising from European ancestry, UK and Finnish healthcare systems, prescription ascertainment, and use of a UK Biobank LD reference for Finnish data.

↳ Discussion, limitations paragraphs

Limitations

#methodological rigour

Prescription proxy lacks direct validation

The phenotype assumes 30-day prescriptions and combines diverse analgesics, while prolonged prescribing can reflect factors other than chronic pain. No direct comparison with diagnosis-based or patient-reported pain in the same cohorts is presented.

↳ Methods, Phenotype Definitions; Discussion, limitations paragraph

#contribution

Headline counts are inconsistently presented

The Abstract reports 78 novel and 62 previously reported associations, but Table 1 sums to approximately 85 novel and 55 previously reported signals. The total of 140 also aggregates results across 11 overlapping phenotypes rather than representing 140 unique loci.

↳ Abstract; Table 1; Discussion, paragraph 1

#reporting

Biological interpretations exceed tested contrasts

Sex specificity is inferred from significant-versus-nonsignificant findings without a reported heterogeneity test, and functional enrichments remain hypothesis-generating rather than validated mechanisms.

↳ Results, Sex-Stratified Analysis and Functional Analysis; Discussion, paragraph 3

Does this match your read? Add your assessment ↓

Nabu Commentary

The study’s scale, two-biobank design, and extensive downstream analyses support a meaningful contribution to association mapping for analgesic-use phenotypes. Methodological Rigour is limited by the assumption that extended prescriptions directly identify chronic pain and by the absence of sensitivity analyses separating pain from prescribing behaviour, opioid response, or dependence. The Abstract’s novel/known split is not reproduced by Table 1, and the 140-signal total is not equivalent to a count of unique loci. The Discussion addresses several population and ascertainment limitations, but mechanistic and sex-specific interpretations remain stronger than the reported analyses warrant.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
3.4±0.2

Contribution
3.6

The study meaningfully extends prescription-derived pain genetics through a large two-biobank meta-analysis and several downstream analyses. Its contribution is moderated by overlapping phenotype counts, an inconsistent novel/known split, and limited functional validation.

Abstract; Results, Discovery of 140 Genetic Associations; Table 1

These combined meta-analyses identified 140 genome-wide associations

Methodological Rigour
3.1

The GWAS, meta-analysis, rare-variant, colocalisation, TWAS, and enrichment procedures are extensively described using established tools. The central phenotype remains an unvalidated treatment-use proxy, and the headline signal count aggregates overlapping phenotypes without conditional analysis.

Methods, Phenotype Definitions and Association Analyses; Table 1

We assumed that each analgesic prescription is for 30 days duration.

Reporting
3.5

The article follows a coherent sequence from phenotype construction through association discovery and functional interpretation. Precision is reduced by numerical discrepancies and by sex-specific and mechanistic interpretations that exceed the reported tests.

Results, Sex-Stratified Analysis; Figure 5 legend; Methods, SNP-Based Heritability and Genetic Correlations

male pain perception may be more genetically driven than female pain perception

Positioning
3.5

The paper engages prior pain GWAS and discusses ancestry, healthcare-system, LDSC, and ascertainment limitations. It does not fully propagate the multifactorial nature of analgesic prescribing into every claim about chronic-pain genes and mechanisms.

Introduction; Discussion, final three paragraphs

prescription drug use can be influenced by many factors

Reliability

Caveats4 of 4 checks


Results checkNoted
  • We detected many associations at loci previously reported in the literature, demonstrating that our prescription-based definitions of chronic pain are capturing relevant disease information: "including 78 novel (e.g. ARPP21, CNTNAP2) and 62 previously reported (e.g. SLC39A8, DCC, TRPM8) associations." (Abstract) vs "PainChronic painChronic pain patients defined as >90 days prescribed analgesics vs healthy controls (GP linkage and no chronic pain)128,985563,05435,550156,14193,435406,913482820Strong opioid use vs healthyStrong opioids ever prescribed vs healthy controls (GP linkage and no chronic pain)71,837563,05416,505156,14155,223406,913362016Strong opioid > 90 days vs healthyStrong opioids prescribed for more than 90 days vs healthy controls (GP linkage and no chronic pain)31,944563,0548100156,14123,844406,9131587Time on analgesics Q4 vs healthyQuartile 4 of the time on analgesics compared to participants not receiving analgesics32,474563,0549063156,14123,411406,91321129Cessation Time Q4 vs healthyQuartile 4 of the time to stop analgesics compared to participants not receiving analgesics32,412563,0548992156,14123,420406,91313103Pain severityStrong opioid use > 90 days vs neverStrong opioids ever prescribed vs patients with >90 days prescribed analgesics but never prescribed strong opioids31,91557,085807118,98223,84438,103220Strong opioid >90 days vs <90 daysStrong opioids prescribed for more than 90 days vs Strong opioids prescribed for less than 90 days31,91523,6828071529123,84418,391000Pain durationTime on analgesics Q4 vs Q1Quartile 4 of the time on analgesics compared to Quartile 1 of the time on analgesics32,43233,0749021870923,41124,365110Time on analgesics Q4 vs Q1-Q3Quartile 4 of the time on analgesics compared to all others with time on analgesics32,43296,427902126,40323,41170,024220Cessation Time Q4 vs Q1Quartile 4 of the time to stop analgesics compared to Quartile 1 of the time to stop analgesics32,38232,2598962889423,42023,365000Cessation Time Q4 vs Q1-Q3Quartile 4 of the time to stop analgesics compared to all others time to stop analgesics32,38296,477896226,46223,42070,015220" (Table 1, phenotype rows). Summing Table 1's novel-signal counts gives 28+20+8+12+10+2+0+1+2+0+2=85, and summing its previously reported counts gives 20+16+7+9+3=55, preserving the total of 140 and the finding of many previously reported associations. → Conclusion holds
Reporting and transparencyNoted

The candidate-gene enumeration contains nine names despite stating seven, and the genetic-correlation reporting gives conflicting Bonferroni test counts. Neither issue establishes a changed association result.

Conflict of interest: not stated · Ethics approval: declared · Data availability: declared · Code availability: declared

Reference IntegrityClean

93 of 93 checkable references verified

97 references in manuscript 4 have no canonical index record — counted, but not index-checkable 5 references confirmed by manual review

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Musculoskeletal · Other musculoskeletal disorders
Type of advanceEmpirical
Route to useSuggested
AdvanceAdvances
BeneficiariesCatch-all cause
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessFoundational
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The findings are observational genetic associations and computational enrichment analyses in population biobanks, with no experimental or interventional demonstration of any mechanism working.

From the paper
“the evaluation of safer therapeutic opportunities in axonal guidance molecules deserves further exploration”

The paper names possible real-world uses of its findings, such as therapeutic targets for chronic pain, but does not specify who would act on them or in what setting.

Pathway

Pharmaceutical and target-discovery researchers would take the prioritised genes and pathways, such as SEMA3F and axonal guidance, forward as candidate targets for new analgesic therapies.

Barrier

The genetic associations and implicated mechanisms require functional validation in cellular and animal models before any therapeutic target can be confidently pursued.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Genome-wide meta-analysis of quantitatively measured generalized anxiety symptoms in individuals of European ancestry

    Skelton, Mitchell, Assary, et al. · 2026 · Clinical medicine

    Primary claim

    We identified 80 independent genome-wide significant variants within 74 loci, 39 of which were newly associated with anxiety.

    Well-supported
    Evidence Score
    4.0±0.2
    Reliability
    Caveats
  2. Co-expression-based models improve eQTL predictions for transcriptome-wide association studies and highlight new schizophrenia-associated genes

    Rossi, Sportelli, Kikidis, et al. · 2026 · Clinical medicine

    Primary claim

    Applying this framework to Psychiatric Genomics Consortium wave 3 genotypes identified 766 genes associated with schizophrenia

    Tentative
    Evidence Score
    3.0±0.2
    Reliability
    Caveats
  3. Shared proteomic landscape between arteriosclerosis and cardiovascular endpoints: a Mendelian randomization and observational study integrating AlphaFold3 for structural prediction

    Huang, Meena, Achtari, et al. · 2026 · Clinical medicine

    Primary claim

    We prioritized 10 proteins potentially causally associated with both the arteriosclerotic/atherosclerotic markers and cardiovascular events.

    Supported
    Evidence Score
    3.3±0.2
    Reliability
    Caveats

How the rubric works →